The efficacy of magnesium oxide and sodium valproate in prevention of migraine headache: a randomized, controlled, double-blind, crossover study.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc in the context of migraine, published as a randomized controlled trial.

Migraine is a disabling disorder that affects the quality of life of patients.

This is a single-center, randomized, controlled, crossover trial which is double-blind, 24-week, 2-sequence, 2-period, 2-treatment.

Who Took Part

The abstract describes 31 patients taking part.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and crossover study.

The patients were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Neither the patients nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

In the crossover set-up each of the patients took both Vitamin D, K2, Magnesium and Zinc and the comparison in turn, acting as their own control.

What Was Measured

Topics PubMed links to this paper include Antacids, Anticonvulsants, Magnesium Oxide, Migraine Disorders and Valproic Acid.

Author keywords: Clinical trial, Crossover, Migraine headache and Valproate sodium.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Vitamin D, K2, Magnesium and Zinc in 31 patients in people with migraine.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2021 (Acta neurologica Belgica), a journal based in Italy.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Migraine research.